Laura Scott
Key details
- Job title: Partner
- Firm: William Fry
- Jurisdiction: Ireland
Laura Scott is one of the most influential women in Irish intellectual property law, noted for her expertise in coordinating complex litigation strategies and for her role in some of the most significant patent disputes heard in Ireland, particularly those involving major global life sciences companies.
She frequently advises multinational pharmaceutical and technology companies on strategy in litigation before the Irish courts, often in cases with broader European or global implications.
Her work also spans supplementary protection certificates and regulatory-linked patent disputes, reflecting the strong overlap between Irish IP law and EU pharmaceutical regulation.
Scott’s significant cases include acting for Eli Lilly in Commercial Court proceedings seeking revocation of a Novartis patent and in the defence of infringement proceedings, including a competition law counterclaim against Novartis, relating to Lilly’s product Taltz (ixekizumab) for the treatment of psoriasis.
She has also acted for ViiV Healthcare in patent infringement proceedings against Gilead Sciences concerning an anti-retroviral HIV treatment, Biktarvy (bictegravir), as well as in the defence of Gilead’s counterclaim for invalidity.
She has represented Skyscanner in defending Commercial Court proceedings brought by Ryanair, including a competition law counterclaim against Ryanair, and has acted for Genentech in supplementary protection certificate (SPC) patent infringement proceedings against Amgen relating to an anti-VEGF antibody used in cancer treatment.
She has also acted for Eli Lilly in patent revocation proceedings concerning a patent owned by Eisai Pharmaceuticals relating to the treatment of Alzheimer’s disease.
In addition, Scott has acted for Merck Sharpe & Dohme (MSD) in defending Commercial Court patent infringement proceedings brought by Bristol-Myers Squibb, Ono Pharmaceutical and Tasuku Honjo relating to anti-PD-1 antibodies used in cancer treatment and MSD’s product Keytruda, including MSD’s counterclaim for invalidity.